COVINGTON & BURLING LLP

1201 PENNSYLVANIA AVENUE NW
WASHINGTON, DC 20004-2401
TEL 202.662.6000
FAX 202.662.6291
WWW.COV.COM

WASHINGTON
NEW YORK
SAN FRANCISCO
LONDON
BRUSSELS

PATRICK S. DAVIES
TEL 202.662.5274
FAX 202.778.5274
PDAVIES@COV.COM

March 24, 2008

CONFIDENTIAL TREATMENT REQUESTED

DELIVERED BY HAND

The Honorable John D. Dingell
Chairman
United States House of Representatives
Committee on Energy and Commerce
Washington, DC 20515-6115

The Honorable Bart Stupak
Chairman
United States House of Representatives
Committee on Energy and Commerce
Subcommittee on Oversight and Investigations
Washington, DC 20515-6115

Re: Request to Schering-Plough Corporation and Merck & Co., Inc.

Dear Chairman Dingell and Chairman Stupak:

This letter constitutes a supplemental response on behalf of Schering-Plough Corporation ("Schering-Plough"), Merck & Co., Inc. ("Merck"), and Merck/Schering-Plough Pharmaceuticals (collectively, "M/SP Pharmaceuticals") to your requests for certain documents and information related to the ENHANCE clinical trial (collectively, the "Requests").

M/SP Pharmaceuticals continues to work diligently to gather the documents and information sought in the Requests, and will continue to produce information and documents on a rolling basis in accordance with our discussions and agreement with the Committee.

As before, we request that the Committee treat this letter and any subsequent information provided in response to the Requests as confidential and that the Committee provide us with notice and an opportunity to object prior to making any portion of our response public.

We are producing with this supplemental response approximately 800 documents (5,000 pages). These additional materials reflect communications between M/SP Pharmaceuticals and advertising agencies or public relations firms regarding Vytorin and the ENHANCE trial and are responsive to Request 3 of the Committee's January 16, 2008 letter. Per our discussions with Committee staff, we also are producing documents reflecting the "run times" for Vytorin advertisements and additional DDMAC correspondence regarding Vytorin. For ease of reference, these materials bear Bates numbers MSPP 063284 - MSPP 068217.

We also are producing with this supplemental response approximately 3,500 documents (43,000 pages) responsive to various Committee requests relating to the ENHANCE trial. These additional materials are responsive to those requests seeking:

1. Records relating to the ENHANCE trial generated by the expert panel (Request No. 4, December 11, 2007);

2. Communications between Dr. John Kastelein and Schering-Plough and Merck, as well as all communications between Dr. Kastelein and members of the "outside advisory" panel (Request No. 1, January 16, 2008);

3. Records relating to the January 14, 2008 press release announcing the ENHANCE results (Request No. 2, January 16, 2008);

4. Records of all briefings to corporate officers of Schering-Plough or Merck relating to the ENHANCE trial (Request No. 6, January 18, 2008);

5. Records relating to the data reviewed by biostatisticians (Request No. 2, February 11, 2008);

6. Records of any and all versions of ENHANCE protocols, SAPs, Operator Manuals and Reader Manuals (Request No. 3, February 11, 2008); and

7. Communications with FDA relating to the ENHANCE protocol and SAP (Request No. 4, February 11, 2008).

For ease of reference, these documents bear Bates numbers MSPP 068218 - MSPP 111383.

Please feel free to contact us if you have any questions regarding this response.

Sincerely,

By: 

Patrick S. Davies
Counsel to Schering-Plough Corporation, Merck & Co., Inc., and Merck/Schering-Plough Pharmaceuticals

Enclosures

cc: Deepak Khanna, Vice President & General Manager
Merck/Schering-Plough Pharmaceuticals